CLNN
Clene·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CLNN
Clene Inc.
A clinical-stage biopharmaceutical company that develops nanotherapeutics for the treatment of neurodegenerative diseases
6550 South Millrock Drive, Suite G50, Salt Lake City, Utah
--
Clene Inc., was founded on November 13, 2017. Clene is a clinical-stage biopharmaceutical company developing unique therapies for neurodegenerative diseases. Clene has invented a new nanotechnology drug platform for the development of new oral neurotherapeutic drugs. Clene is also bringing an ionic zinc and silver aqueous solution for antiviral and antibacterial use to the clinic.
Company Financials
EPS
CLNN has released its 2025 Q3 earnings. EPS was reported at -0.85, versus the expected -0.56, missing expectations. The chart below visualizes how CLNN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CLNN has released its 2025 Q3 earnings report, with revenue of 15.00K, reflecting a YoY change of -82.76%, and net profit of -8.78M, showing a YoY change of -9.90%. The Sankey diagram below clearly presents CLNN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
